The Life Sciences team advised BELLUS Health Inc. (TSX and Nasdaq: BLU) on its underwritten public offering in Canada and the United States of 16,540,541 common shares at a price to the public of $9.25 per common share. The total gross proceeds were $153 million, before deducting the underwriting commissions and any expenses related to the offering. BELLUS Health has also granted to the underwriters an option exercisable by the underwriters within 30 days of the date of the underwriting agreement to purchase up to an additional 2,481,081 common shares of the company.
BELLUS Health Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other hypersensitization-related disorders.
The Goodwin team was led by Danielle Lauzon, Finnbar Murphy, Amanda Rae Schwarzenbart, Sara Lepis, Alexander Varond (Regulatory) and Dan Karelitz (Tax).
For more details, read the press release.